Emergomyces orientalis
Emergomycosis Diagnosed by Metagenomic Next-Generation Sequencing

Da He¹, Min Quan¹, Hongyan Zhong, Zhixing Chen, Xiaohui Wang, Fang He, Junyan Qu, Taoyou Zhou, Xiaoju Lv, Zhiyong Zong

Author affiliations: Center for Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China (D. He, M. Quan, Z. Chen, X. Wang, F. He, J. Qu, T. Zhou, X. Lv, Z. Zong); Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region, Chengdu (H. Zhong); West China Hospital of Sichuan University, Chengdu (Z. Chen); Center for Infectious Diseases, Yaan People’s Hospital, Yaan, China (X. Wang)

DOI: https://doi.org/10.3201/eid2710.210769

Emergomyces orientalis is a newly described dimorphic fungus genus; it may cause fatal infections in immunocompromised patients, but diagnosis is often delayed. We report a case of disseminated emergomycosis caused by the novel species Emergomyces orientalis in a kidney transplant recipient from Tibet. Infection was diagnosed early by metagenomic next-generation sequencing.

Emergomycosis (formerly called emmonsiosis) is an emerging dimorphic fungal disease, usually caused by Emergomyces pasteurianus or Es. africanus, usually disseminated and commonly identified and fatal in immunocompromised patients, especially HIV-positive patients from South Africa (1,2). Diagnosis of emergomycosis is often delayed, and best clinical practices for diagnosing and treating organ transplant recipients are lacking. Five species with different geographic distributions have been described: Es. pasteurianus, Es. africanus, Es. canadensis, Es. europaeus, and Es. orientalis. Globally, the only case of Es. orientalis infection, reported in China in 2017, was initially misdiagnosed as disseminated cryptococcosis (3). We report another case of Es. orientalis infection involving lung and soft tissue damage that was diagnosed early and accurately and treated precisely.

A 41-year-old man from Tibet who had received a kidney transplant 6 years earlier was admitted to a hospital with a 1-month history of progressive right lower chest pain and mild cough with a small amount of sputum. He was taking tacrolimus, mycophenolate mofetil, and prednisone. He was a herder caring for sheep, horses, and dogs. We noted reduced breath sounds in his lower right lung; chest computed tomography images indicated pneumonia (Figure, panel A). A bronchoalveolar lavage fluid smear revealed yeast-like fungi on both Gram staining and Grocott-Gomori methenamine silver staining (Figure, panel B). Because pulmonary cryptococcosis was suspected, fluconazole (400 mg 1×/d) was initiated. Results of a cryptococcal antigen lateral flow immunooassay (IMMY, https://www.immy.com) was negative, but a Platelia Aspergillus antigen immunoenzymatic sandwich microplate assay (Bio-Rad, https://www.bio-rad.com) resulted in an unexpectedly high level (6.42 [reference 0.00–0.49] signal:cutoff ratio). After 1 week of ineffective empirically prescribed treatment, we had a lung biopsy performed. Electron microscopy revealed yeast cells in a unique form, measuring ≈3 μm, scattered in necrotizing granulomas (Figure, panel C). Metagenomic next-generation sequencing (mNGS) of fresh tissue indicated Es. orientalis (sequence reads 143; Illumina NextSeq 550 platform, https://www.illumina.com; Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/27/10/21-0769-App1.pdf). We initiated oral itraconazole (200 mg 2×/d) immediately and decreased tacrolimus dosage according to its plasma concentration. Finally, we isolated the pure Es. orientalis strain (Figure, panel D). Specific secondary, α-shaped conidiophores clearly indicated Emergomyces (Figure, panel E). Es. orientalis was confirmed by PCR amplification targeting the rDNA internal transcribed spacer region followed by BLAST sequence comparison (https://blast.ncbi.nlm.nih.gov/Blast.cgi; GenBank accession no. NR_148064.1; coverage 96%, identity 99.33%) (Appendix Figure 2).

During treatment, the patient had intermittent mild fever and an acne-like rash on his chin, and a small new pulmonary lesion developed in the right upper lobe. Repeated blood cultures were all negative. We prescribed oral posaconazole (400 mg 2×/d) after determining a MIC of 0.008 μg/mL (Appendix Table). Later, the lung lesions partially resolved, but we found a painful soft tissue abscess (55 × 15 × 30 mm) on the right side of his waist (Figure, panel F) from which we drained purulent grayish-green fluid. We again cultured Es. orientalis. Therefore, we added fluconazole (1,000 mg 3×/d) and withdrew tacrolimus and mycophenolate mofetil for 1 month. After 6 months of recurrent hospitalization, we discharged the

¹These authors contributed equally to this article.
patient with a diagnosis of disseminated emergomycosis. Six months after discharge, he remained stable. We found no similarly infected or epidemiologically linked person or animal.

Previously, a retrospective study from southern Africa assessed 54 patients with disseminated emergomycosis, of whom 94% were co-infected with HIV; 96% had skin involvement, 88% had lung involvement, 44% received an incorrect diagnosis, and 48% died (4). In this case, we initially identified *Es. orientalis* infection using mNGS, a 1-step, culture-independent method for detecting all pathogens from 1 specimen (5). Although research validating mNGS assays in clinical practice is very limited, challenging cases diagnosed by mNGS have been published and expert consensus has begun to recommend mNGS for diagnosing challenging cases in immunocompromised patients (6,7). Therefore, we recommend using mNGS to diagnose challenging emergomycosis cases.

This case showed that treatment with posaconazole combined with flucytosine is effective in organ transplant recipients with disseminated emergomycosis caused by *Es. orientalis*. Although amphotericin B deoxycholate is more effective than triazoles for improving emergomycosis survival rate (71% vs. 33%) (4), we could not prescribe it for our patient because of nephrotoxicity. Similar to the earlier reported case of *Es. orientalis* infection, in which type 2 diabetes was the only identified cause of immunodeficiency (3), fluconazole was ineffective in vivo in our patient. Previously, 3 cases in China of *Es. pasteurianus* (formerly *Emmonsia pasteuriana*) infection with or without renal transplantation have also been reported (8–10).

Further research is needed to determine whether kidney transplantation is associated with *Es. orientalis* infection and risk for emergomycosis. In conclusion, clinicians need to become more aware of emergomycosis because of its common misdiagnosis and high death rate.

**Acknowledgments**

We thank Liubo Xiong and Yuling Xiao for their help.

This study was supported by Sichuan Science and Technology program, China (2018HH0031) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (2017-046).
About the Author
Dr. He and Dr. Quan are medical students at the Center for Infectious Diseases, West China Hospital of Sichuan University in Chengdu, China. Their research interests are pathogen detection and microbial resistance.

References

Address for correspondence: Xiaohui Wang, Center for Infectious Diseases, West China Hospital of Sichuan University, Wuhouqu Guoxuexiang 37#, Chengdu 610041, China; email: wang_xiaohui@scu.edu.cn

Human Infection with Avian Influenza A(H9N2) Virus, Cambodia, February 2021

Samnang Um, Jurre Y. Siegers, Borann Sar, Savuth Chin, Sarika Patel, Seng Bunnary, Makara Hak, Sothy So, Oum Sokhen, Seng Heng, Darapheak Chau, Tom Sothyra, Asheena Khalakdina, Joshua A. Mott, Sonja J. Olsen, Filip Claes, Ly Sovann, Erik A. Karlsson

Author affiliations: National Institute of Public Health, Ministry of Health, Phnom Penh, Cambodia (S. Um, S. Chin, D. Chau); Institut Pasteur du Cambodge, Phnom Penh (J.Y. Siegers, E.A. Karlsson); US Centers for Disease Control and Prevention, Phnom Penh (B. Sar); World Health Organization Country Office, Phnom Penh (S. Patel, A. Khalakdina); National Animal Health and Production Research Institute, Phnom Penh (S. Bunnary, T. Sothyra); Food and Agriculture Organization of the United Nations Country Office, Phnom Penh (M. Hak); Prevention and Control Disease Bureau, Provincial Health Department, Siem Reap, Cambodia (S. Sor); Provincial Office of Animal Health and Production, Siem Reap (O. Sokhen); Cambodian Center for Disease Control, Ministry of Health, Phnom Penh (S. Heng, L. Sovann); US Centers for Disease Control and Prevention, Bangkok, Thailand (J.A. Mott, S.J. Olsen); Food and Agriculture Organization of the United Nations Regional Office for Asia and the Pacific, Bangkok (F. Claes)

DOI: https://doi.org/10.3201/eid2710.211039

In February 2021, routine sentinel surveillance for influenza-like illness in Cambodia detected a human avian influenza A(H9N2) virus infection. Investigations identified no recent H9N2 virus infections in 43 close contacts. One chicken sample from the infected child’s house was positive for H9N2 virus and genetically similar to the human virus.

Low pathogenicity avian influenza virus subtype A(H9N2) is endemic in poultry in Asia, the Middle East, and Africa (1). These viruses do not cause mass mortality in poultry but can cause substantial negative economic impacts (2). H9N2 viruses also have zoonotic potential; 74 human infections were reported from 1998 through early 2021 (1,3,4), mainly in children with a history of poultry exposure. The internal gene casettes of H9N2 viruses contribute to human adaptation of avian influenza viruses (AIV)
Emergomyces orientalis Emergomycosis Diagnosed by Metagenomic Next-Generation Sequencing Appendix

**Appendix Table.** Antimicrobial susceptibility test results*

<table>
<thead>
<tr>
<th>Antimicrobials</th>
<th>MIC, μg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>amphotericin B</td>
<td>0.2</td>
</tr>
<tr>
<td>5-fluorocytosine</td>
<td>0.06</td>
</tr>
<tr>
<td>fluconazole</td>
<td>1</td>
</tr>
<tr>
<td>itraconazole</td>
<td>0.015</td>
</tr>
<tr>
<td>voriconazole</td>
<td>0.015</td>
</tr>
<tr>
<td>posaconazole</td>
<td>0.008</td>
</tr>
<tr>
<td>anidulafungin</td>
<td>8</td>
</tr>
<tr>
<td>caspofungin</td>
<td>1</td>
</tr>
<tr>
<td>micafungin</td>
<td>8</td>
</tr>
</tbody>
</table>

*Performed in the yeast phase using the fungal broth microdilution method.
Appendix Figure 1. *Emergomyces orientalis* coverage map. The identified reads were mapped to the *Es. orientalis* reference genome (GenBank accession no. GCA_002110485.1). The abscissa is the genome position of *Es. orientalis* reference genome. The left-side scale shows the number of matched mNGS sequences in the alignment. The right-side scale shows the sequencing depth (i.e., the number of times the base pair site has been sequenced). The blue bars show the number of matched mNGS sequences corresponding to various positions in the genome of the fungus. The red line represents the average sequence depth distribution at different positions in the bacterial genome. M, position in the genome in millions of base pairs (x-axis scale)
Appendix Figure 2. Phylogenetic tree of the ITS sequences amplified from the isolate in this study and sequences from reference strains in GenBank. A maximum likelihood tree was inferred using IQ-TREE under the TIM2+F+I+G4 model, chosen by the program according to the Bayesian information criterion and subjected to a 10,000-iteration bootstrap test to check the robustness. The supporting values were colored in gradients and the branch lengths were measured in terms of the number of substitutions per site. The scale bar represents number of substitutions per site.